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Abstract 
The objective of the present study was to develop and evaluate an oral 
pulsatile drug delivery system to mimic the circadian rhythm of the 
disease by releasing the drug with a distinct predetermined lag time of 6 
h (± 0.25 h). The basic design of the system consisted of a rapid release 
tableted core and a controlled release tableted coat. A combination of 
Isopropyl Alcohol (70%) and Acetone (30%) was used as solvent for 
Eudragit S100 coating. An in vitro dissolution study of the prepared 
tablet was conducted initially for 2 h in simulated gastric fluid and after 
that medium was changed to intestinal fluid pH 7.4.  
Keywords: Pulsatile drug delivery system, Lag time, Circadian rhythm, 
Eudragit S100. 
Introduction 
Oral control drug delivery offers a number of 
advantages over conventional immediate release 
preparations. These systems are designed to 
deliver the drug at controlled and predetermined 
rate thus maintaining their therapeutic effective 
concentration in systemic circulation for 
prolonged periods. On the other hand, for certain 
therapies a pulsatile drug release pattern, where 
the drug is released after well-defined lag time 
[1]. It is well documented that most of the body 
functions display circadian rhythms, e.g. heart 
rate, stroke volume, blood pressure, blood flow, 
body temperature, gastric- pH. Moreover, in a 
number of organs their functions vary with the 
time of the day. It is increasingly recognized that 
there are rhythmic and temporal patterns in the 
manifestation of many disease states. 
Traditionally drugs are released in an immediate 
or extended pattern. However in recent year’s 
pulsatile release systems are gaining growing 
interest, where the drug is released rapidly after a 
well defined lag time, could be adventitious for 
many drugs or therapies. Pulsatile drug delivery 
is one that releases a therapeutic agent at a 
rhythm that ideally matches biological 
requirement of a given disease therapy [2]. 
Diseases where constant drug levels are not 
preferred, but needs a pulse of therapeutic 
concentration in a periodic manner acts as a push 
for the development of “Pulsatile Drug Delivery 
Systems”. Disease like Asthma results in 
increased airway responsiveness & worsening of 
lung function. These symptoms typically occur 
between midnight & especially around 4 am. 
Thus this study attempts to design & evaluate a 
chronomodulated drug delivery system of 
Theophylline, a bronchodilator for the treatment 
of asthma. It was aimed to have a lag time of 6h. 
i.e. the system is taken at the bed time and 
expected to release the drug after a period of 6h. 
i.e. at the 4 am when the asthma attacks are more 
prevalent. Such time controlled pulsatile delivery 
can be achieved mainly with drug containing 
cores. Which are covered with release controlling 
layers. The core serves as reservoir and the 
release-controlling layer protect the core from the 
environment e.g. water, acidic pH and enzymes 
until the drug is released after a predetermined 
lag phase. The coatings can erode/dissolve, 
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rupture or alter their permeability at the required 
time [3]. 
 
The pulsatile effect, i.e., the release of drug as a 
“pulse” after a lag time has to be designed in such 
a way that a complete and rapid drug release 
should follow the lag time [4, 5]. Such systems 
are also called time-controlled as the drug 
released is independent of the environment. 
Pulsatile drug delivery systems are gaining a lot 
of interest and attention these days.  
 
These systems have a peculiar mechanism of 
delivering the drug rapidly and completely after a 
lag time i.e., a period of “no drug release.” 
Though most delivery systems are designed for 
constant drug release over a prolonged period of 
time, pulsatile delivery systems are characterized 
by a programmed drug release, as constant blood 
levels of a drug may not always be desirable. 
Pulsatile systems are designed in a manner that 
the drug is available at the site of action at the 
right time in the right amount. These systems are 
beneficial for drugs having high first-pass effect, 
drugs administered for diseases that follow 
chronopharmacological behavior, drugs having 
specific absorption site in GIT, targeting to colon 
and cases where night time dosing is required.   
 
 
 
 
 
 
Advantages of pulsatile drug delivery: [6] 
1. Extended daytime or nighttime activity. 
2. Reduced side effects. 
3. Reduced dosage frequency. 
4. Reduction in dose size. 
5. Improved patient compliance. 
6. Lower daily cost to patient due to fever dosage 
units are required by the patient in  therapy. 
7. Drug targeting to specific sites like colon. 
8. Protection of mucosa from irritating drugs. 
9. Drug loss is prevented from first pass effect. 
 
Materials and method  
Material 
Theophylline was obtained as a gift sample from 
Kores Pharmaceuticals Pvt. India. Eudragit S 100 
obtained as a gift sample from Wockhardt 
Research Centre, Aurangabad. Microcrystalline 
cellulose, Magnessium stearate, Acetone and 
Potassium dihydrogen phosphate were purchased 
from local authorized dealer. 
 
The core tablets were prepared by direct 
compression method. An accurately weighed 250 
mg of drug and other ingredients like sodium 
starch glycolate, lactose and magnesium stearate 
were mixed by triturating in glass mortal-pestle. 
The blend was directly compressed at weight of 
312 mg using 10 mm punch on ten-station rotary 
tablet machine (Karnavati Engg. Ltd., India. 
Model: Rimek Minipress 2D). The compositions 
of the formulation batches are given in Table 1. 
Table 1: Formulation of Core Tablet 
Ingredient 
CR 
1 
CR 
2 
CR3 
CR 
4 
CR 
5 
CR 
6 
CR7
CR 
8 
CR 
9 
CR 
10 
CR 
11 
CR 
12 
Theophylline (mg.) 250 250 250 250 250 250 250 250 250 250 250 250 
Lactose (mg.) 50 50 50 50 50 50 - - - - - - 
MCC (mg.) - - - - - - 50 50 50 50 50 50 
SSG (%) 1 2 3 4 5 6 1 2 3 4 5 6 
Mg. Stearate (%) 1 1 1 1 1 1 1 1 1 1 1 1 
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Methods 
Formulation of core tablet 
The core tablets were prepared by using two 
different diluents in 12 different formulations to 
impart burst effect so as to rupture the coating 
and immediate release of the drug [7]. 
 
Evaluation of Core Tablet  
Core tablets were evaluated for hardness, weight 
variation, friability and in vitro dissolution 
behavior according to standard pharmacopoeial 
procedures. The hardness of the tablets was 
determined by the Monsanto hardness tester 
(Spacelab, India. Model: 13-1). To calculate 
weight variation, 20 tablets were weighed 
individually and the average was calculated. 
Individual weight was then compared to the 
average weight. Weight variation was found to 
fall within the USP limit (± 0.5%) [8, 9]. 
Friability test was carried out using 20 tablets. 
The tablets were pre-weighed and placed in a 
Roche friabilator (Electrolab, India. Model: EF 
1W) operated for 100 revolutions. Tablets were 
then dedusted and reweighed. The difference in 
weights was used to calculate the friability [10].  
 
Formulation of Coated Tablet 
The core tablets were coated with a 
Polymethacrylate copolymer (12.5%) to release 
the drug in the lower part of the small intestine 
where the pH is around 7 [11]. The 
Polymethacrylate copolymer Eudragit S100 
having solubility at pH 7 will dissolve in the 
intestinal pH. As the intestinal fluid will penetrate 
in the core tablet, the superdisintegrant will cause 
the tablet to release the drug by rupturing the 
coating. 
 
Di-butyl phthalate was used as plasticizer to 
make the coating more pliable [12]. The coating 
solutions were prepared using (70:30) ratio of 
IPA: Acetone solution in 100 % extra quantity to 
overcome the handling waste [13]. 
 
In vitro Drug Release Study for Coated 
Tablet:   
The In-Vitro dissolution studies of the pulsatile 
tablet formulation of Theophylline were carried 
out using dissolution test apparatus USP-II 
paddle type. The dissolution medium consisted of 
900 ml of standard buffer of pH 1.2 for the first 2 
h followed by pH 7.4 for the remaining time 
period upto 8 to 10 h. The temperature of the 
medium was maintained at 37±0.50C. The speed 
of rotation of the basket was kept at 100 rpm. 
Aliquots of 1 ml were withdrawn after every half 
hour. These samples were diluted to make up the 
volume of 10 ml with pH 1.2 buffer for first 2 
hours and then by pH 7.4 buffer. The samples so 
withdrawn were replaced with the fresh 
dissolution medium equilibrated at the same 
temperature. The drug released at the different 
time intervals from the dosage form is measured 
by UV visible spectrophotometer, by measuring 
the absorbance for the samples solutions at 272 
nm. 
 
 
Table 2: Formulation of Coated Tablet 
Formulations CTD 1 CTD 2 CTD 3 CTD 4 CTD 5 CTD 6 CTD 7 CTD 8 
Eudragit S100 (%) 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 
Avg.% Wt Gain 1 1 1 1.5 1.5 1.5 2 2 
Di-butyl phthalate (%) 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 
IPA:Acetone (70:30)  100 100 100 100 100 100 100 100 
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Factorial Design [14]  
In this study, A 32 randomized full factorial 
design was used where two factors were 
evaluated, each at 3 levels and experimental trials 
were performed at all 9 possible combinations. 
The amount of superdisintegrant (SSG) and 
weight gain after coating were selected as 
independent variables. Table 3 summarizes 
dependent and independent variables and the 
resulted formulations are listed in table 3. 
 
Table 3: Experimental design: Factors and Responses. 
 
Stability Studies [15] 
The stability studies were carried out on the 
optimized formulations, at 400C/ 75% RH for a 
period of one month. The sample tablets were 
wrapped in the laminated aluminum foils and 
were placed in the accelerated stability chamber 
at 400C/75% RH for a period of one month. 
Sampling was done at a predetermined time 
intervals of 0, 7, 14, 21 and 28 days. The tablets 
were evaluated for physical appearance, assay, % 
release of the drug and lag time. 
 
Result and discussion 
Drug Excipients Compatibility Study  
The IR spectrums were obtained using FTIR 
Spectrophotometer. The FT-IR spectra of the 
pure Theophylline and physical mixture of drug–
polymer were recorded to check interaction 
between drug and polymers. The characteristic 
peak due to pure Theophylline has appeared in 
the spectra without any markable change in the 
position. It indicates that there was no chemical 
interaction between Theophylline and polymers 
[16-19]. 
 
Evaluation of core tablets: 
Hardness and friability: [20] 
The tablets showed hardness values ranging from 
4 to 5 kg/cm2. Another measure of a tablets 
strength is friability. Conventional compressed 
tablets that lose less than 1% of their weight are 
generally considered acceptable. In present study, 
the friability values for all the tablet formulations 
were found to be <1%, indicating that the 
friability is within the prescribed limits.  
 
 
Table 4: Evaluation of core tablets 
Formulations Hardness (kg/cm2) 
Weight Uniformity 
(mg) ± SD 
Friability 
(%) Thickness 
Uniformity 
of content 
Disintegration 
time (sec.) 
CR 1 4.8 307± 1.70 0.621 2.8±0.3 100±1.02 673 
CR 2 4.9 308±1.67 0.554 2.8±0.3 101±1.12 532 
CR 3 4.8 310±2.34 0.741 2.8±0.4 101±1.04 379 
CR4 4.5 313±2.9 0.358 2.9±0.5 98±0.98 298 
CR 5 4 .6 320±2.88 0.558 8±0.5 99±0.94 247 
CR6 4 .3 323±2.93 0.658 3±0.4 102±1.26 191 
CR 7 4 .7 306±1.89 0.554 2.7±0.4 100±1.01 221 
CR 8 4 .4 309±2.01 0.741 2.7±0.5 101±1.02 153 
CR 9 4 .3 313±2.22 0.358 2.8±0.4 97±1.12 71 
CR 10 3.9 317±2.78 0.558 3±0.5 98±0.99 10- 15 
CR 11 4.00 320±2.56 0.658 2.9±0.3 100±0.81 10- 15 
CR12 4 .2 322±2.56 0.554 3±0.5 99±1.07 10- 15 
Values as mean ± SD, n=5. 
 
Coded 
Factor Level 
Factor 1 
SSG (%) 
Factor 2 
Wt. Gain (%) 
-1 Low 2 1 
0 Intermediate 4 1.5 
1 High 6 2 
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Table 5: Lag time (t10) of CTD 1 –CTD 8 
Formulation lag time (t10) in minutes 
CTD 1 147 
CTD 2 172 
CTD 3 207 
CTD 4 254 
CTD 5 312 
CTD 6 346 
CTD 7 377 
CTD 8 438 
 
Weight Uniformity:  
The pharmacopoeial limits for deviation for 
tablets of more than 250 mg are ± 5%. The values 
are found between 306±1.89 and 323±2.93. The 
average percentage deviation for all tablet 
formulations was found to be within the specified 
limits and hence all formulations complied with 
the test for weight variation. 
 
Thickness:  
Tablets from all batches showed thickness values 
in the range of 2.7±0.3 to 3±0.5 mm. 
 
Uniformity of drug content:    
Good uniformity in drug content was found 
within and among the different types of tablet 
formulations. The values ranged from 97±1.12 % 
to 101±1.023 % of labeled amount. Hence the 
tablet prepared passes the pharmacopoeial limit. 
 
Disintegration time: 
As per the requirements of pulsatile tablets the 
core tablet should give rapid and transient 
release. The tablets prepared by using lactose as 
diluents give disintegration time from 191 to 663 
second, where as the tablets prepared by using 
microcrystalline cellulose shows disintegration 
time between 221 to 10-15 second. Where 
Sodium starch glycolate was used as 
superdisintegrant in both case. The studies 
showed that the tablet hardness affects the 
disintegration time, harder the tablet more the 
disintegration time. Hardness from 4 to 5 gives 
best disintegration results being in its own limits. 
 
Evaluation of Coated tablet: 
Determination of lag time (t10):  
The dissolution profile of all 8 batches shows 
increase in the lag time with increase in the 
percent weight gain. The weight gain directly 
increases the coating thickness so the lag time 
too. The aim of the study was to develop a tablet 
which will be protected from gastric environment 
and will release the drug rapidly in the intestine 
after 5-6 hours of administration. So the above 
batches showed increase in lag time from 147 to 
438 minutes with respect to their coating level.  
The lag time was determined while performing 
the dissolution test and the values are shown in 
Table 5 and Figure 1 and 2. 
 
Figure 1: Graphical representation of effect of coating level on lag time. 
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Table 6: Weight uniformity, Thickness and Disintegration time of PT 1 to PT 9 
Formulation Weight uniformity (mg) ± SD Thickness Disintegration time (min) 
PT 1 322±1.3 2.8±0.02 198 
PT 2 328±1.21 2.9±0.02 187 
PT 3 332±1.65 3.0±0.04 181 
PT 4 327±0.06 2.9±0.03 293 
PT 5 332±1.47 3.0±0.03 287 
PT 6 340±1.11 3.1±0.05 279 
PT 7 334±1.53 3.0±0.03 384 
PT 8 338±0.97 3.2±0.05 382 
PT 9 346±1.05 3.3±0.02 279 
    Values for thickness are expressed as mean ± SD, n=5. 
 
In vitro Dissolution studies: 
In Vitro Dissolution profile for formulations CTD 1 to CTD 8 shown in Figure 2. 
 
Figure 2: Common Dissolution Profile of CTD 1 to CTD 8 
 
Table 7: Determination of lag time of PT 1 to PT 9: 
Formulation lag time (t10) in minutes 
PT 1 262 
PT 2 256 
PT 3 251 
PT 4 361 
PT 5 359 
PT 6 352 
PT 7 454 
PT 8 453 
PT 9 451 
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Table 8: Stability studies of 1 month  
Stability (40 ±20C, 75 ±5% RH) Physical appearance Assay Drug Release (%) Lag Time (t10) 
0 day √ 99.45 97.43 359 
1 Week √ 98.97 96.79 357 
2 Week √ 98.45 96.25 353 
3 Week √ 98.12 95.87 349 
4 Week √ 97.91 95.56 345 
 
Evaluation of pulsatile tablet prepared 
by applying factorial 
Design: 
Weight variation:  
The pharmacopoeial limits for deviation for 
tablets of more than 250 mg are ± 5%. The values 
are found between 322±1.3 and 346±1.05. The 
average percentage deviation for all tablet 
formulations was found to be within the specified 
limits and hence all formulations complied with 
the test for weight variation. 
 
 
 
 
 
Thickness 
Tablets from all batches showed thickness values 
in the range of 2.7±0.3 to 3±0.5 mm. 
 
Disintegration time:  
After coating with impermeable anionic polymer 
i.e. Eudragit S100 the disintegration time of the 
tablet was increased. The disintegration time 
increased with increase of percentage level of 
coating with polymer and decreased with increase 
of concentration of sodium starch glycolate.  The 
tablet didn’t disintegrated, or showed any crack 
on it in simulated gastric fluid for 1h after that it 
showed increase in the disintegration time from 
181 to 384 minutes.  
 
Figure 3:  Lag time of PT 1 – PT 9 
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Figure 4: Common dissolution profile of PT 1 - PT 9 
 
 
Determination of lag time 
After coating with impermeable anionic polymer 
i.e. Eudragit S100 the lag time of the tablet was 
increased. The lag time increased with increase of 
percentage level of coating with polymer and 
decreased with increase of concentration of 
sodium starch glycolate. The lag time was found 
between the range of 251 to 454 minutes.  
 
In vitro dissolution test: 
The In- vitro drug release studies revealed that 
the release of Theophylline from different 
formulations varies with concentration of 
superdisintegrants and percent weight gain of pH 
soluble polymers (Eudragit S100).  
 
Sodium starch glycolate have superdisintegrant 
property as well as swelling property. It not only 
plays role of disintegration but it also help to 
rupture the polymer coating. Increase in the level 
of sodium starch glycolate reduces the lag time 
whereas increase in the coating level increases 
the lag time. In vitro dissolution data of all PT 1- 
PT 9 batches showing comparative release 
pattern. 
 
Stability Studies  
The stability studies of optimum formulation 
revealed that there is no significant reduction in 
the assay, drug release and lag time (t10) of the 
active drug was observed and physical 
appearance of the formulation was not altered 
over a period of one month. 
Conclusion 
A coated PDDS for Theophylline to mimic the 
circadian rhythm of the disease by releasing the 
drug at appropriate time (At the time of 
symptoms). The system was found to be 
satisfactory in terms of release of the drug after a 
predetermined lag time of 6 h and thus the dosage 
forms can be taken at bedtime so that the content 
will be released in the morning hours i.e. at the 
time of symptoms. The release of drug was rapid 
and complete after the lag time. Lag time can be 
controlled by adjusting the percent weight gain as 
well as the superdisintegrant concentration.  
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